HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G

Journal of Biological Chemistry

Volumn 288, Issue 9, 2013, Pages 6083-6094

  Feng, Yuqing ^a   Love, Robin P ^a   Chelico, Linda ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL ASSAY; DOUBLE STRANDED DNA; HUMAN IMMUNODEFICIENCY VIRUS; HYPER MUTATION; MOLECULAR MECHANISM; PROTEASOMAL DEGRADATION; RETROVIRAL RESTRICTION; SINGLE-STRANDED DNA; SLIDING MOVEMENTS; UBIQUITINATION; VIRAL INFECTIVITY FACTORS;

AMINES; ASSAYS; MUTAGENESIS; VIRUSES;

DNA;

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DOUBLE STRANDED DNA; SINGLE STRANDED DNA; VIF PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEAMINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; VIRUS REPLICATION;

AMINO ACID SUBSTITUTION; CYTIDINE DEAMINASE; DNA, SINGLE-STRANDED; DNA, VIRAL; HIV-1; HUMANS; MODELS, BIOLOGICAL; MUTATION, MISSENSE; PROTEOLYSIS; PROVIRUSES; UBIQUITINATION; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 84874759842     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.421875     Document Type: Article

References (84)

1. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650
2. Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L., and Trono, D. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103
3. Harris, R. S., Bishop, K. N., Sheehy, A. M., Craig, H. M., Petersen-Mahrt, S. K., Watt, I. N., Neuberger, M. S., and Malim, M. H. (2003)DNAdeamination mediates innate immunity to retroviral infection. Cell 113, 803-809
4. Zhang, H., Yang, B., Pomerantz, R. J., Zhang, C., Arunachalam, S. C., and Gao, L. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98
5. Strebel, K., and Khan, M. A. (2008) APOBEC3G encapsidation into HIV-1 virions: which RNA is it? Retrovirology 5, 55
6. Suspène, R., Sommer, P., Henry, M., Ferris, S., Guétard, D., Pochet, S., Chester, A., Navaratnam, N., Wain-Hobson, S., and Vartanian, J. P. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32, 2421-2429
7. Yu, Q., König, R., Pillai, S., Chiles, K., Kearney, M., Palmer, S., Richman, D., Coffin, J. M., and Landau, N. R. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435-442
8. Coffin, J. M., Hughes, S. H., and Varmus, H. E. (1997) Retroviruses, pp. 121-160, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
9. Rausch, J. W., and Le Grice, S. F. (2004) 'Binding, bending and bonding': polypurine tract-primed initiation of plus-strand DNA synthesis in human immunodeficiency virus. Int. J. Biochem. Cell Biol. 36, 1752-1766
10. Hu, C., Saenz, D. T., Fadel, H. J., Walker, W., Peretz, M., and Poeschla, E. M. (2010) The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F. J. Virol. 84, 11981-11993
11. Suspène, R., Rusniok, C., Vartanian, J. P., and Wain-Hobson, S. (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 34, 4677-4684
12. Chelico, L., Pham, P., Calabrese, P., and Goodman, M. F. (2006) APOBEC3GDNAdeaminase acts processively 3' → 5' on single-stranded DNA. Nat. Struct. Mol. Biol. 13, 392-399
13. von Hippel, P. H., and Berg, O. G. (1989) Facilitated target location in biological systems. J. Biol. Chem. 264, 675-678
14. Stanford, N. P., Szczelkun, M. D., Marko, J. F., and Halford, S. E. (2000) One- and three-dimensional pathways for proteins to reach specific DNA sites. EMBO J. 19, 6546-6557
15. Halford, S. E., and Marko, J. F. (2004) How do site-specific DNA-binding proteins find their targets? Nucleic Acids Res. 32, 3040-3052
16. Senavirathne, G., Jaszczur, M., Auerbach, P. A., Upton, T. G., Chelico, L., Goodman, M. F., and Rueda, D. (2012) Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution. J. Biol. Chem. 287, 15826-15835
17. Shlyakhtenko, L. S., Lushnikov, A. Y., Miyagi, A., Li, M., Harris, R. S., and Lyubchenko, Y. L. (2012) Nanoscale structure and dynamics of ABOBEC3G complexes with single-stranded DNA. Biochemistry 51, 6432-6440
18. Chelico, L., Pham, P., and Goodman, M. F. (2009) Stochastic properties of processive cytidineDNAdeaminases AID and APOBEC3G. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364, 583-593
19. Feng, Y., and Chelico, L. (2011) Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. J. Biol. Chem. 286, 11415-11426
20. Haché, G., Liddament, M. T., and Harris, R. S. (2005) The retroviral hypermutation specificity of APOBEC3F andAPOBEC3Gis governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280, 10920-10924
21. Navarro, F., Bollman, B., Chen, H., König, R., Yu, Q., Chiles, K., and Landau, N. R. (2005) Complementary function of the two catalytic domains of APOBEC3G. Virology 333, 374-386
22. Chelico, L., Prochnow, C., Erie, D. A., Chen, X. S., and Goodman, M. F. (2010) Structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 285, 16195-16205
23. Wedekind, J. E., Gillilan, R., Janda, A., Krucinska, J., Salter, J. D., Bennett, R. P., Raina, J., and Smith, H. C. (2006) Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem. 281, 38122-38126
24. Bennett, R. P., Salter, J. D., Liu, X., Wedekind, J. E., and Smith, H. C. (2008) APOBEC3G subunits self-associate via the C-terminal deaminase domain. J. Biol. Chem. 283, 33329-33336
25. McDougall, W. M., Okany, C., and Smith, H. C. (2011) Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes. J. Biol. Chem. 286, 30655-30661
26. Huthoff, H., Autore, F., Gallois-Montbrun, S., Fraternali, F., and Malim, M. H. (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5, e1000330
27. Bulliard, Y., Turelli, P., Röhrig, U. F., Zoete, V., Mangeat, B., Michielin, O., and Trono, D. (2009) Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. J. Virol. 83, 12611-12621
28. Sheehy, A. M., Gaddis, N. C., and Malim, M. H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407
29. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X. F. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060
30. Stopak, K., de Noronha, C., Yonemoto, W., and Greene, W. C. (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591-601
31. Marin, M., Rose, K. M., Kozak, S. L., and Kabat, D. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398-1403
32. Conticello, S. G., Harris, R. S., and Neuberger, M. S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13, 2009-2013
33. Bishop, K. N., Holmes, R. K., Sheehy, A. M., Davidson, N. O., Cho, S. J., and Malim, M. H. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14, 1392-1396
34. Zennou, V., and Bieniasz, P. D. (2006) Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 349, 31-40
35. Chaipan, C., Smith, J. L., Hu, W. S., and Pathak, V. K. (2013) APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J. Virol. 87, 444-453
36. Marin, M., Golem, S., Rose, K. M., Kozak, S. L., and Kabat, D. (2008) Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J. Virol. 82, 987-998
37. Jäger, S., Kim, D. Y., Hultquist, J. F., Shindo, K., LaRue, R. S., Kwon, E., Li, M., Anderson, B. D., Yen, L., Stanley, D., Mahon, C., Kane, J., Franks-Skiba, K., Cimermancic, P., Burlingame, A., Sali, A., Craik, C. S., Harris, R. S., Gross, J. D., and Krogan, N. J. (2012) Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection. Nature 481, 371-375
38. Zhang, W., Du, J., Evans, S. L., Yu, Y., and Yu, X. F. (2012) T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481, 376-379
39. Mehle, A., Strack, B., Ancuta, P., Zhang, C., McPike, M., and Gabuzda, D. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279, 7792-7798
40. Iwatani, Y., Chan, D. S., Liu, L., Yoshii, H., Shibata, J., Yamamoto, N., Levin, J. G., Gronenborn, A. M., and Sugiura, W. (2009) HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 106, 19539-19544
41. Mariani, R., Chen, D., Schröfelbauer, B., Navarro, F., König, R., Bollman, B., Münk, C., Nymark-McMahon, H., and Landau, N. R. (2003) Speciesspecific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31
42. Schröfelbauer, B., Chen, D., and Landau, N. R. (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U.S.A. 101, 3927-3932
43. Bogerd, H. P., Doehle, B. P., Wiegand, H. L., and Cullen, B. R. (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U.S.A. 101, 3770-3774
44. Mangeat, B., Turelli, P., Liao, S., and Trono, D. (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279, 14481-14483
45. Miller, J. H., Presnyak, V., and Smith, H. C. (2007) The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 4, 81
46. Kao, S., Khan, M. A., Miyagi, E., Plishka, R., Buckler-White, A., and Strebel, K. (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging ofAPOBEC3G(CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77, 11398-11407
47. Kao, S., Miyagi, E., Khan, M. A., Takeuchi, H., Opi, S., Goila-Gaur, R., and Strebel, K. (2004) Production of infectious human immunodeficiency virus type 1 does not require depletion ofAPOBEC3Gfrom virus-producing cells. Retrovirology 1, 27
48. Goila-Gaur, R., Khan, M. A., Miyagi, E., and Strebel, K. (2009) Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif. J. Virol. 83, 1156-1160
49. Goila-Gaur, R., Khan, M. A., Miyagi, E., Kao, S., Opi, S., Takeuchi, H., and Strebel, K. (2008) HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 372, 136-146
50. Camaur, D., and Trono, D. (1996) Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J. Virol. 70, 6106-6111
51. Kao, S., Akari, H., Khan, M. A., Dettenhofer, M., Yu, X. F., and Strebel, K. (2003) Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J. Virol. 77, 1131-1140
52. Fouchier, R. A., Simon, J. H., Jaffe, A. B., and Malim, M. H. (1996) Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J. Virol. 70, 8263-8269
53. Karczewski, M. K., and Strebel, K. (1996) Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J. Virol. 70, 494-507
54. Mercenne, G., Bernacchi, S., Richer, D., Bec, G., Henriet, S., Paillart, J. C., and Marquet, R. (2010) HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res. 38, 633-646
55. Sadler, H. A., Stenglein, M. D., Harris, R. S., and Mansky, L. M. (2010) APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 84, 7396-7404
56. Nowarski, R., Britan-Rosich, E., Shiloach, T., and Kotler, M. (2008) Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat. Struct. Mol. Biol. 15, 1059-1066
57. Xu, H., Chertova, E., Chen, J., Ott, D. E., Roser, J. D., Hu, W. S., and Pathak, V. K. (2007) Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360, 247-256
58. Britan-Rosich, E., Nowarski, R., and Kotler, M. (2011) Multifaceted counter- APOBEC3G mechanisms employed by HIV-1 Vif. J. Mol. Biol. 410, 1065-1076
59. Santa-Marta, M., da Silva, F. A., Fonseca, A. M., and Goncalves, J. (2005) HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 280, 8765-8775
60. Greene, W. C., Debyser, Z., Ikeda, Y., Freed, E. O., Stephens, E., Yonemoto, W., Buckheit, R. W., Esté, J. A., and Cihlar, T. (2008) Novel targets for HIV therapy. Antiviral Res. 80, 251-265
61. Zuo, T., Liu, D., Lv, W., Wang, X., Wang, J., Lv, M., Huang, W., Wu, J., Zhang, H., Jin, H., Zhang, L., Kong, W., and Yu, X. (2012) Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J. Virol. 86, 5497-5507
62. Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D. D., and Bieniasz, P. D. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1, e6
63. Jern, P., Russell, R. A., Pathak, V. K., and Coffin, J. M. (2009) Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5, e1000367
64. Pillai, S. K., Wong, J. K., and Barbour, J. D. (2008) Turning up the volume on mutational pressure: is more of a good thing always better? (a case study of HIV-1 Vif and APOBEC3). Retrovirology 5, 26
65. Nguyen, K. L., llano, M., Akari, H., Miyagi, E., Poeschla, E. M., Strebel, K., and Bour, S. (2004) Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319, 163-175
66. Le Grice, S. F., and Grüninger-Leitch, F. (1990) Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 187, 307-314
67. Gao, F., Robertson, D. L., Morrison, S. G., Hui, H., Craig, S., Decker, J., Fultz, P. N., Girard, M., Shaw, G. M., Hahn, B. H., and Sharp, P. M. (1996) The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J. Virol. 70, 7013-7029
68. Briggs, J. A., Simon, M. N., Gross, I., Kräusslich, H. G., Fuller, S. D., Vogt, V. M., and Johnson, M. C. (2004) The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11, 672-675
69. Zhu, P., Chertova, E., Bess, J., Jr., Lifson, J. D., Arthur, L. O., Liu, J., Taylor, K. A., and Roux, K. H. (2003) Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl. Acad. Sci. U.S.A. 100, 15812-15817
70. Creighton, S., Bloom, L. B., and Goodman, M. F. (1995) Gel fidelity assay measuring nucleotide misinsertion, exonucleolytic proofreading, and lesion bypass efficiencies. Methods Enzymol. 262, 232-256
71. Loeb, D. D., Swanstrom, R., Everitt, L., Manchester, M., Stamper, S. E., and Hutchison, C. A., 3rd. (1989) Complete mutagenesis of the HIV-1 protease. Nature 340, 397-400
72. Chelico, L., Sacho, E. J., Erie, D. A., and Goodman, M. F. (2008) A model for oligomeric regulation of APOBEC3G cytosine deaminase-dependent restriction of HIV. J. Biol. Chem. 283, 13780-13791
73. Huthoff, H., and Malim, M. H. (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81, 3807-3815
74. Lavens, D., Peelman, F., Van der Heyden, J., Uyttendaele, I., Catteeuw, D., Verhee, A., Van Schoubroeck, B., Kurth, J., Hallenberger, S., Clayton, R., and Tavernier, J. (2010) Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res. 38, 1902-1912
75. Cadima-Couto, I., Saraiva, N., Santos, A. C., and Goncalves, J. (2011) HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay. J. Neuroimmune Pharmacol. 6, 296-307
76. Bernacchi, S., Henriet, S., Dumas, P., Paillart, J. C., and Marquet, R. (2007) RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J. Biol. Chem. 282, 26361-26368
77. Henriet, S., Richer, D., Bernacchi, S., Decroly, E., Vigne, R., Ehresmann, B., Ehresmann, C., Paillart, J. C., and Marquet, R. (2005) Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA. J. Mol. Biol. 354, 55-72
78. Henriet, S., Mercenne, G., Bernacchi, S., Paillart, J. C., and Marquet, R. (2009) Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol. Mol. Biol. Rev. 73, 211-232
79. Uyttendaele, I., Lavens, D., Catteeuw, D., Lemmens, I., Bovijn, C., Tavernier, J., and Peelman, F. (2012) Random mutagenesis MAPPIT analysis identifies binding sites for Vif and Gag in both cytidine deaminase domains of Apobec3G. PLoS One 7, e44143
80. Albin, J. S., LaRue, R. S., Weaver, J. A., Brown, W. L., Shindo, K., Harjes, E., Matsuo, H., and Harris, R. S. (2010) A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J. Biol. Chem. 285, 40785-40792
81. Smith, J. L., and Pathak, V. K. (2010) Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 84, 12599-12608
82. Kitamura, S., Ode, H., Nakashima, M., Imahashi, M., Naganawa, Y., Kurosawa, T., Yokomaku, Y., Yamane, T., Watanabe, N., Suzuki, A., Sugiura, W., and Iwatani, Y. (2012) The APOBEC3C crystal structure and the interface for HIV-1 Vif binding. Nat. Struct. Mol. Biol. 19, 1005-1010
83. Nathans, R., Cao, H., Sharova, N., Ali, A., Sharkey, M., Stranska, R., Stevenson, M., and Rana, T. M. (2008) Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26, 1187-1192
84. Browne, E. P., Allers, C., and Landau, N. R. (2009) Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387, 313-321